# VAC Regimen for AML Patients Who Failed to Response to VA Regimen

> **NCT06220162** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 32 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** chidamide in combination with venetoclax and azacitidine (VAC)

## Key facts

- **NCT ID:** NCT06220162
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-01
- **Primary completion:** 2026-12-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-03-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06220162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06220162, "VAC Regimen for AML Patients Who Failed to Response to VA Regimen". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06220162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*